The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function

Launched by UNIVERSITY OF COPENHAGEN · Dec 22, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how certain hormones, specifically GIP, GLP-1, and GLP-2, affect people who have genetic variations in the receptors for these hormones. These hormones play a role in how our bodies manage blood sugar and appetite. The researchers want to understand their effects better in individuals with these genetic differences.

If you’re between the ages of 19 and 74 and have a body mass index (BMI) between 19 and 35, you may be eligible to participate. However, certain health conditions, like liver disease, kidney problems, or uncontrolled high blood pressure, may exclude you from joining. Participants will receive infusions of these hormones and help researchers learn more about their effects. It's an opportunity to contribute to important research while receiving close monitoring during the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • BMI 19-35 kg/m2
• Exclusion Criteria:
• • Treatment with medication or supplements that can not be discontinued for 12 hours
• • \>10 objects of alcohol weekly or abuse of narcotics
• • Liver disease (defined as ALAT and/or ASAT ≥ 2 x normal levels)
• • Decreased kidney function (creatine levels over reference interval)
• • Uncontrollable increased blood pressure (\> 140/90 mmHg)
• • Low blood percentage (hemoglobin \< 8.3 mmol/l)
• • Special diet or planned weight change during trial period
• • Other conditions that could be expected to affect the primary or secondary outcomes